두경부암 환자에서 화학요법 및 면역요법과 함께 세미플리맙에 대한 연구
절제 가능하고 국소적으로 진행된 두경부 편평세포암종 환자에서 백금-이중항 화학요법과 Cetuximab을 병용한 신보강 Cemiplimab의 파일럿 연구
The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Lara Dunn, MD
- 전화번호: 646-608-3787
- 이메일: dunnl1@mskcc.org
연구 연락처 백업
- 이름: David Pfister, MD
- 전화번호: 646-888-4237
- 이메일: pfisterd@MSKCC.ORG
연구 장소
-
-
New Jersey
-
Basking Ridge, New Jersey, 미국, 07920
- 모병
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
-
연락하다:
- Lara Dunn, MD
- 전화번호: 646-608-3787
- 이메일: dunnl1@mskcc.org
-
Middletown, New Jersey, 미국, 07748
- 모병
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
연락하다:
- Lara Dunn, MD
- 전화번호: 646-608-3787
-
Montvale, New Jersey, 미국, 07645
- 모병
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
연락하다:
- Lara Dunn, MD
- 전화번호: 646-608-3787
-
-
New York
-
Commack, New York, 미국, 11725
- 모병
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)
-
연락하다:
- Laura Dunn, MD
- 전화번호: 646-608-3787
-
Harrison, New York, 미국, 10604
- 모병
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
연락하다:
- Lara Dunn, MD
- 전화번호: 646-608-3787
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center
-
연락하다:
- Lara Dunn, MD
- 전화번호: 646-608-3787
-
Rockville Centre, New York, 미국, 11553
- 모병
- Memorial Sloan Kettering Nassau (Limited Protocol Activites)
-
연락하다:
- Laura Dunn, MD
- 전화번호: 646-608-3787
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the head and neck that has arisen from the oral cavity, oropharynx, nasal cavity, paranasal sinuses, larynx, or hypopharynx
-
Clinical stage T1, N2-3; T2, N1-3, T3/T4a, Any N (AJCC, 8th ed.) without evidence of distant metastasis (M0) based on PET/CT or CT chest, abdomen, and pelvis, for which standard-of-care treatment would entail surgical resection with adjuvant radiation +/- chemotherapy.
° Patients with recurrent and multiple primary head and neck cancers that are surgically resectable are eligible if the patient did not receive prior radiation or systemic therapy.
-
Disease must be amenable to surgical resection.
-
The patient must be a surgical candidate.
-
Adequate organ and bone marrow function documented by:
- Hemoglobin > 9.0 g/dL
- Absolute neutrophil count (ANC) >1.5 x 10^9/L
- Platelet count >100 x 10^9/L
- Serum creatinine <1.5 upper limit of normal (ULN) or estimated creatinine clearance (CrCl) >30 mL/min
- Adequate hepatic function:
-
Total bilirubin <1.5 x upper limit of normal ULN)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both < 3 x ULN
-
Alkaline phosphatase (ALP) <2.5 x ULN Note: For patients with Gilbert syndrome, total bilirubin <3x ULN. Upper central must be documented appropriately as past medical history.
-
Men and woman >18 years old
-
Eastern cooperative oncology group performance status < 1 CPS ≥ 20 and
Inclusion criteria for the tertiary cohort will remain the same as prior with the following exceptions:
- Pathologically (histologically) proven diagnosis of oral cavity squamous cell carcinoma HPV-negative by p16 or ISH
- Clinical Stage will be limited to cT2 with cN0-N2b, cM0 with only 1 lymph node >2.0 cm in the short axis without evidence of distant metastasis (M0) based on PET/CT or CT chest, abdomen, and pelvis.
- Curative intent surgical management is determined to require a free flap, mandibulectomy, glossectomy, or other significant surgical morbidity.
Exclusion Criteria:
- Prior radiation and systemic therapy for a head and neck cancer.
- Oral cavity cancer that is not amenable to surgical resection or the patient is not a surgical candidate.
- Active or prior documented autoimmune or inflammatory disorders that have been treated with steroids or immunomodulator therapy in the past 5 years.
Exceptions: Patients with vitiligo, type 1 diabetes mellitus, and endocrinopathies (including hypothyroidism due to autoimmune thyroiditis) only requiring hormone replacement, childhood asthma that is resolved, or psoriasis it does not require systemic treatment are permitted.
-
Conditions requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressant medications within 14 days of treatment on study.
-
Receipt of live attenuated vaccine within 30 days prior initiating treatment on study.
-
Prior allogeneic stem cell transplantation, or autologous stem cell transplantation.
-
Any infection requiring hospitalization and/or intravenous antibiotic therapy within 2 weeks of the start of treatment.
-
Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HBV or HCV) infection; or diagnosis of immunodeficiency.
- Patients with known HIV infection who have controlled infection (undetectable viral load (HIV RNA PCR) and CD4 count above 350, either spontaneously or on a stable antiviral regimen) are permitted. For patients with controlled HIV infection monitoring will be performed per local standards
- Patients with HBV (hepatitis B surface antigen positive; HBsAg+) who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for HBV) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA. Patients must remain on anti-viral therapy for at least 6 months be on the last dose of Cemiplimab.
- Patients were HCV antibody positive (HCV Ab+) who have controlled infection (undetectable HCV RNA by PCR, either spontaneously or in response to successful prior course of anti-HCV therapy) are permitted.
-
History of immune-related pneumonitis with the last 5 years.
-
History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of leuko-corticoids to assist with management.
-
Known hypersensitivity or allergy to any of the excipients in the cemiplimab drug product.
-
Patients with a history of solid organ transplant (exception: corneal transplant)
-
Any medical comorbidity, physical examination finding, or metabolic dysfunction, or clinical laboratory abnormality that in the opinion of the investigator renders the patient unsuitable for participation in a clinical trial due to high safety risks.
-
Women with a positive serum or urine beta-hCG pregnancy test at screening/baseline visit. If positive, pregnancy must be ruled out by ultrasound for patient to be eligible.
-
Breast-feeding women
-
Women of childbearing potential who are sexually active and aren't willing to practice highly effective contraception prior to the first dose of Cemiplimab, during the study, and for at least 180 days after the last dose. Highly effective contraceptive measures include:
- Stable use of combined estrogen and progesterone containing hormonal contraception or progesterone and-only hormonal contraception associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening
- Intrauterine device; intrauterine hormone-releasing system
- Bilateral tubal ligation
- Vasectomized partner and/or
- Sexual abstinence
Exclusion criteria for the tertiary cohort will remain the same as prior with the following exceptions:
- History of head and neck cancer. This includes patients who present with a recurrence of a previously treated oral cavity squamous cell carcinoma.
- Synchronous primary squamous cell carcinomas of the oral cavity.
- Presence of diffuse oral mucosa dysplasia or leukoplakia that per the judgement of the clinical investigator represents a clinically and independent significant risk of developing a second oral cavity primary
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Head and Neck Squamous Cell Cancer/HNSCC
Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible. |
Cisplatin 75mg/m2 AUC 5 on weeks 2, 5, and 8 Carboplatin AUC 5 on weeks 2, 5, and 8 Docetaxel 75mg/m2 on weeks 2, 5, and 8 Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10 Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37 Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s). Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic stage following induction systemic therapy and surgery is ypT1-2N0 without the presence of adverse features that include positive margins or a combination of perineural invasion, vascular invasion, and a depth of invasion of >0.5mm, adjuvant radiation will not be administered, consistent with the NCCN guidelines [2]. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques. If participants are unable to receive Docetaxel due to lack of insurance approval or due to an allergic reaction, Docetaxel can be substituted with Paclitaxel. Paclitaxel would be dosed at 90 mg/m2 on weeks 2, 3, 5, 6, 8 and 9.
다른 이름들:
|
|
실험적: Secondary Cohort
Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible. |
Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10 Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37 |
|
실험적: Tertiary Cohort: Oral cavity squamous cell carcinoma (OCSCC)
A tertiary cohort of 20 patients with oral cavity squamous cell carcinoma (OCSCC) |
Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10 Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37 |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of toxicities graded according to NCI CTCAE
기간: 1 year
|
The primary endpoint is safety and tolerability, which will be evaluated by a description of observed adverse events by grades. All toxicities will be graded according to NCI CTCAE, Version5.0. The regimen will be deemed safe and well tolerated if there are 2 or fewer DLTs out of 10 patients enrolled. A DLT is defined as any non-hematologic grade 3 or greater adverse event as defined by CTCAE v5.0 that is thought to be related to the addition of Cemiplimab to the combination of a platinum-doublet with cetuximab. |
1 year
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Lara Dunn, MD, Memorial Sloan Kettering Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 부위별 신생물
- 신생물
- 조직학적 유형에 따른 신생물
- 신생물, 선상 및 상피
- 암종
- 암종, 편평 세포
- 두경부의 편평 세포 암종
- 두경부 신생물
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 탄화수소
- 사이클로 파라핀
- 탄화수소, alicyclic
- 탄화수소, 순환
- 테르펜
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 무기 화학 물질
- 염소 화합물
- 질소 화합물
- 조정 복합체
- 박습니다
- 사이클로 데카네
- Diterpenes
- 백금 화합물
- 도세탁셀
- 세툭시맙
- 카르보플라틴
- 파클리탁셀
- 시스플라틴
- Cemiplimab
기타 연구 ID 번호
기타 연구 ID 번호
- 20-445
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .